MedTrace Logo

Autologous and Allogeneic Transplant for Relapsed Lymphoma

NCT00802113 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2019-03-27

Study results available
· View outcomes & findings →

Summary

The sequential combination of myeloablative therapy and autologous stem cell transplantation (APBSCT) followed by a reduced intensity allogeneic stem cell transplant (Allo SCT) and post SCT adoptive cellular immunotherapy will be well tolerated in patients with refractory or recurrent non-Hodgkin's lymphoma (NHL) and Hodgkin's disease (HD).

Conditions

  • Non-Hodgkin's Lymphoma
  • Hodgkins Disease

Interventions

DRUG

Fludarabine

Fludarabine 30 mg/m2 x 5 days

DRUG

Busulfan

Busulfan 3.2 mg/kg/day x 2 days

DRUG

Anti-Thymocyte Globulin

Anti-Thymocyte Globulin 2.0 mg/kg/day x 4 days

Sponsors & Collaborators

Principal Investigators

  • Prakash Satwani, MD · Columbia University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-06-30
Primary Completion
2014-10-31
Completion
2014-10-22

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00802113 on ClinicalTrials.gov